CD276

CD276 Antibody Clinical Trials & Market Sales Forecasts, 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 29, 2023

The "Global CD276 Antibody Clinical Trials & Market Sales Forecast 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global CD276 Antibody Clinical Trials & Market Sales Forecast 2028" report has been added to ResearchAndMarkets.com's offering.
  • Meanwhile, there are several drug candidates that have been steadily moving forward in their respective clinical trials hoping to be the first approved CD276 inhibitor.
  • Current leaders in the CD276 targeted checkpoint inhibitors include; Daiichi Sankyo, YmAb Therapeutics, AbbVie, BioAtla, Fate Therapeutics, MacroGenics, and several others.
  • Global CD276 Antibody Market Opportunity Assessment: > US$ 1 Billion
    Global CD276 Antibody Clinical Trials: > 30 Drugs In Trials
    CD276 Antibody Clinical Trials By Company, Indication & Phase

MD ANDERSON AND RADIOPHARM THERANOSTICS LAUNCH JOINT VENTURE TO DEVELOP NOVEL RADIOPHARMACEUTICALS

Retrieved on: 
Wednesday, September 14, 2022

MELBOURNE, Australia, Sept. 13, 2022 /PRNewswire/ -- The University of Texas MD Anderson Cancer Center ('MD Anderson') and Radiopharm Theranostics Limited ('Radiopharm')(ASX: RAD) today announced the launch of Radiopharm Ventures, LLC, a joint venture company created to develop novel radiopharmaceutical therapeutic products for cancer.

Key Points: 
  • MELBOURNE, Australia, Sept. 13, 2022 /PRNewswire/ -- The University of Texas MD Anderson Cancer Center ('MD Anderson') and Radiopharm Theranostics Limited ('Radiopharm')(ASX: RAD) today announced the launch of Radiopharm Ventures, LLC, a joint venture company created to develop novel radiopharmaceutical therapeutic products for cancer.
  • The joint venture will focus initially on developing at least four therapeutic products based on MD Anderson intellectual property.
  • Radiopharm Ventures, LLC is a limited liability company jointly owned by Radiopharm Theranostics (USA), Inc. (a wholly owned subsidiary of Radiopharm) (51%) and MD Anderson (49%).
  • The costs will be shared by Radiopharm and MD Anderson and both parties will share ownership of the resultant intellectual property.

Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8009, an Antibody Drug Conjugate Targeting B7-H3 (CD276) for the Treatment of Advanced Solid Tumors

Retrieved on: 
Tuesday, August 2, 2022

The clinical trial is a multicenter, open-label Phase 1 clinical study in patients with advanced solid tumors to evaluate the safety and tolerability of BAT8009 and to determine the recommended phase 2 dose.

Key Points: 
  • The clinical trial is a multicenter, open-label Phase 1 clinical study in patients with advanced solid tumors to evaluate the safety and tolerability of BAT8009 and to determine the recommended phase 2 dose.
  • Differences in expression levels make B7-H3 an potential target for ADC drug development.
  • BAT8009 was developed using Bio-Theras proprietary anti-B7-H3 antibody and ADC linker-payload that includes a cleavable and systemically stable linker and a small molecule topoisomerase I inhibitor.
  • The Phase 1, multi-center, open-label, dose-escalation clinical trial of BAT8009 is designed to assess the safety and tolerability of BAT8009.

GT Biopharma Presents TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting

Retrieved on: 
Monday, March 21, 2022

BRISBANE, Calif., March 21, 2022 /PRNewswire/ -- GT Biopharma, Inc. ("the Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary tri-specific natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced today, preclinical data to be presented at the hybrid 48th European Society for Blood and Marrow Transplantation Annual Meeting (EBMT). The poster presentation titled, "Tri-specific Killer Engager (TriKE®) against B7-H3 enhances NK cell mediated killing of multiple myeloma," is presented by Aimee Merino, MD, PhD, Assistant Professor of Medicine, Division of Hematology, Oncology and Transplantation at the University of Minnesota. GTB-5550 (B7-H3 TriKE) is the Company's tri-specific killer engager (TriKE) with camelid single-chain Fv fragments against B7-H3 (CD276) and CD16 linked by IL-15 to enhance NK cell killing of myeloma. GTB-5550 is part of GT Biopharma's portfolio of lead TriKE product candidates being investigated as a mono- and combination therapy against multiple myeloma.

Key Points: 
  • GTB-5550 is part of GT Biopharma's portfolio of lead TriKE product candidates being investigated as a mono- and combination therapy against multiple myeloma.
  • Dr. Gregory Berk, President of R&D and Chief Medical Officer noted, "Testing GTB-5550 across several multiple myeloma cell-lines has yielded preclinical evidence suggesting further investigation of this TriKE in the clinic.
  • Background -Natural Killer (NK) cell-based therapies hold great promise in treating multiple myeloma.
  • One method to enhance NK cell specificity against myeloma is antibody dependent cellular cytotoxicity through a CD16 receptor.

Translational Data From the DeCidE1 Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting

Retrieved on: 
Tuesday, November 9, 2021

Twenty-two women with advanced, recurrent ovarian cancer were enrolled in the DeCidE1 study .

Key Points: 
  • Twenty-two women with advanced, recurrent ovarian cancer were enrolled in the DeCidE1 study .
  • These findings suggest that immunogenic tumors are more susceptible to MVP-S treatment, in line with its mechanism of action.
  • These translational data will inform the design of next IMV-sponsored clinical trial in patients with advanced, recurrent ovarian cancer, expected to be initiated in 2022.
  • IMV is currently assessing maveropepimut-S in breast and advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck.

PharmaVentures acts as advisor to Intocell on their ongoing collaboration agreement with Cellectar

Retrieved on: 
Thursday, July 15, 2021

For nearly 30 years, PharmaVentures has acted as advisor on over 900 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies world-wide.

Key Points: 
  • For nearly 30 years, PharmaVentures has acted as advisor on over 900 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies world-wide.
  • PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.
  • IntoCell has also developed proprietary benzodiazepine dimers and modified duocarmycinoids that show high potency with improved safety in preclinical models.
  • Using its novel chemistries, IntoCell is developing a pipeline of proprietary ADCs that includes a B7-H3 programme which is demonstrating excellent preclinical data.

PharmaVentures acts as advisor to Intocell on their ongoing collaboration agreement with Cellectar

Retrieved on: 
Thursday, July 15, 2021

For nearly 30 years, PharmaVentures has acted as advisor on over 900 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies world-wide.

Key Points: 
  • For nearly 30 years, PharmaVentures has acted as advisor on over 900 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies world-wide.
  • PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.
  • IntoCell has also developed proprietary benzodiazepine dimers and modified duocarmycinoids that show high potency with improved safety in preclinical models.
  • Using its novel chemistries, IntoCell is developing a pipeline of proprietary ADCs that includes a B7-H3 programme which is demonstrating excellent preclinical data.

Y-mAbs Enters into Exclusive Distribution Agreement with Adium Pharma S.A. for DANYELZA® (naxitamab-gqgk) and Omburtamab in Latin America

Retrieved on: 
Wednesday, May 19, 2021

B7-H3 is an immune checkpoint molecule that is widely expressed in tumor cells of several cancer types.

Key Points: 
  • B7-H3 is an immune checkpoint molecule that is widely expressed in tumor cells of several cancer types.
  • Under the terms of the agreement, Adium will employ its sales and marketing expertise to distribute DANYELZA and omburtamab, if approved, in the territory.
  • In addition, Adium will submit registration files on behalf of the Company in certain parts of the territory.
  • Adium distributes its products in 18 Latin American & Caribbean countries including Brazil, Mexico and Colombia.